Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
about
Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration?Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results.Quantifying FITC-labeled latex beads opsonized with photoreceptor outer segment fragments: an easy and inexpensive method of investigating phagocytosis in retinal pigment epithelium cells.Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheepFucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro.γ-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway.Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabBridging the gap between traditional cell cultures and bioreactors applied in regenerative medicine: practical experiences with the MINUSHEET perfusion culture system.Lasting controversy on ranibizumab and bevacizumab.Supportive development of functional tissues for biomedical research using the MINUSHEET® perfusion system.The effects of anti-vascular endothelial growth factor agents on human retinal pigment epithelial cells under high glucose conditions.Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after shortterm treatment with intravitreous bevacizumab.Effects of anti-VEGF agents on rat retinal Müller glial cells.Effects of intravitreally injected Fc fragment on rat eyes.Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells.Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?Toll-like receptor 3 activation in retinal pigment epithelium cells - Mitogen-activated protein kinase pathways of cell death and vascular endothelial growth factor secretion.Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.Nicotine reduces VEGF-secretion and phagocytotic activity in porcine RPE.Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.Oxidative Stress Induces Biphasic ERK1/2 Activation in the RPE with Distinct Effects on Cell Survival at Early and Late Activation.
P2860
Q30436143-8B1A658D-016D-488C-9619-40814D302B16Q33785965-9E27C749-A223-47A7-8772-4F4BB0AF16ECQ33805863-CB6A9EA5-6F9E-4FA7-A932-9AF23340B6C3Q33912465-12CC7063-3C34-4C85-BACE-99AFDEFB937BQ35099817-F932E878-5ADF-4674-9B95-31F0DE14CEFEQ35111136-0100A73B-0C16-4423-9E17-6F23409E82BDQ35226694-95F7BFE5-9849-4B46-AF23-A946B7773810Q35610098-002D0D4D-04F4-405D-9426-94122BAB1642Q35641933-69DE4340-24BB-4A74-9A95-2BB9DFFACB8EQ36578195-FB8DFD4E-E288-44A4-8E75-DE2725991AABQ37647798-2B17D59A-91C4-48E4-ADD3-1078C3C056C4Q37729097-1FD183C9-A549-49C7-9003-92DB85C9F5B6Q38633532-4BE55002-5547-4598-942D-23827037B712Q38874774-D82B33F3-326A-41FE-8D5A-8C95EE9D8FF7Q39357577-AFB270FE-6FAE-4E60-8525-C8A94CD46CCEQ39928163-BF0554B3-253C-4C71-9B2C-4D5A2CCE274DQ40065503-B58DEC7A-D7D0-49EE-ABE9-8B390A1BE36FQ40284780-E462B3EE-9C60-4FA8-B13C-0E21FB9B81C6Q40502050-EBB2F23B-34BA-4871-820B-0A1F4389606DQ42363696-BF2DEA4B-610A-4DF6-B1BD-6FC60A255C1FQ42442066-9654113F-DC92-4E23-99D1-E3F93D2341ADQ46526244-A408D01F-40FB-4BD0-8556-F0ABE4EAB9D9Q50237265-E47559DC-0E73-4EAF-BC00-E101F4001BD8Q50426327-913C663A-37CA-4EF0-9E67-7E19C30BC57FQ50436110-3229BB86-1460-41D8-AB2C-E8CA80FD3E8EQ51697739-19D88A12-38D0-4EBA-938A-287EC6CD79B2Q54319970-5D96A71E-9888-4618-B1CA-F86B945C40AF
P2860
Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Different properties of VEGF-a ...... umab accumulates in RPE cells.
@ast
Different properties of VEGF-a ...... umab accumulates in RPE cells.
@en
type
label
Different properties of VEGF-a ...... umab accumulates in RPE cells.
@ast
Different properties of VEGF-a ...... umab accumulates in RPE cells.
@en
prefLabel
Different properties of VEGF-a ...... umab accumulates in RPE cells.
@ast
Different properties of VEGF-a ...... umab accumulates in RPE cells.
@en
P2093
P1476
Different properties of VEGF-a ...... umab accumulates in RPE cells.
@en
P2093
Alexa Karina Klettner
Daniela Wesch
Dieter Kabelitz
Johann Roider
Marie-Luise Kruse
P2888
P304
P356
10.1007/S00417-009-1136-0
P577
2009-07-14T00:00:00Z
P5875
P6179
1052038959